17D yellow fever vaccine elicits comparable long-term immune responses in healthy individuals and immune-compromised patients

Wieten, Rosanne W.; Goorhuis, Abraham; Jonker, Emile F.F.; Bree, Godelieve J. de; Visser, Adriëtte W. de; Genderen, Perry J.J. van; Remmerswaal, Ester B. M.; Berge, Ineke J. M. ten; Visser, Leo G.; Grobusch, Martin P.; Leeuwen, Ester M. M. van

doi:10.1016/j.jinf.2016.02.017

Cited by 41 publications

(35 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Work focused on stimulation of T cell immunity following TBEV infection has been very limited [143,144,145]. Studies with YFV have evaluated the importance of T cells in response to vaccination [146,147,148]. The broad distribution and number of DENV infections has allowed evaluation of T cell mediated immunity in patients with dengue, dengue hemorrhagic fever or dengue shock syndrome since the early 1990s.…”

Section: Gaps In Flavivirus Researchmentioning

confidence: 99%

Historical Perspectives on Flavivirus Research

Holbrook¹

2017

Viruses

135

104

View full text Add to dashboard Cite

The flaviviruses are small single-stranded RNA viruses that are typically transmitted by mosquito or tick vectors. These “arboviruses” are found around the world and account for a significant number of cases of human disease. The flaviviruses cause diseases ranging from mild or sub-clinical infections to lethal hemorrhagic fever or encephalitis. In many cases, survivors of neurologic flavivirus infections suffer long-term debilitating sequelae. Much like the emergence of West Nile virus in the United States in 1999, the recent emergence of Zika virus in the Americas has significantly increased the awareness of mosquito-borne viruses. The diseases caused by several flaviviruses have been recognized for decades, if not centuries. However, there is still a lot that is unknown about the flaviviruses as the recent experience with Zika virus has taught us. The objective of this review is to provide a general overview and some historical perspective on several flaviviruses that cause significant human disease. In addition, available medical countermeasures and significant gaps in our understanding of flavivirus biology are also discussed.

show abstract

Section: Gaps In Flavivirus Researchmentioning

confidence: 99%

Historical Perspectives on Flavivirus Research

Holbrook¹

2017

Viruses

135

104

View full text Add to dashboard Cite

show abstract

“…The participants were subjects who had received the YFV despite a diagnosis of CIMID and no SAE was reported. There was no difference in AEFV occurrence between patients and healthy individuals [35,[41][42][43][44][45][46][47][48].…”

Section: Studies Selected and Data Extractedmentioning

confidence: 99%

“…Five observational studies [41,42,44,45,48] evaluated the neutralizing antibodies to YFV in 180 patients with CIMID using immunosuppressant drugs, including corticosteroids, synthetic or biological. The authors concluded that all immunocompromised patients were able to develop a protective response to the yellow fever booster.…”

Section: Studies Selected and Data Extractedmentioning

confidence: 99%

“…Neutralizing antibodies were measured by PRNT, and an analysis of PBMC (peripheral blood mononuclear cells) and T cells as well as analysis of the cytokine profile produced by CD8+ lymphocytes specific for the yellow fever virus were performed. The results were compared to a control group composed of 41 healthy individuals who were matched for age, sex, and time of vaccination [41,42].…”

Section: Studies Selected and Data Extractedmentioning

confidence: 99%

See 1 more Smart Citation

Brazilian recommendations on the safety and effectiveness of the yellow fever vaccination in patients with chronic immune-mediated inflammatory diseases

et al. 2019

View full text Add to dashboard Cite

Background: In Brazil, we are facing an alarming epidemic scenario of Yellow fever (YF), which is reaching the most populous areas of the country in unvaccinated people. Vaccination is the only effective tool to prevent YF. In special situations, such as patients with chronic immune-mediated inflammatory diseases (CIMID), undergoing immunosuppressive therapy, as a higher risk of severe adverse events may occur, assessment of the risk-benefit ratio of the yellow fever vaccine (YFV) should be performed on an individual level. Main body of the abstract: Faced with the scarcity of specific orientation on YFV for this special group of patients, the Brazilian Rheumatology Society (BRS) endorsed a project aiming the development of individualized YFV recommendations for patients with CIMID, guided by questions addressed by both medical professionals and patients, followed an internationally validated methodology (GIN-McMaster Guideline Development). Firstly, a systematic review was carried out and an expert panel formed to take part of the decision process, comprising BRS clinical practitioners, as well as individuals from the Brazilian Dermatology Society (BDS), Brazilian Inflammatory Bowel Diseases Study Group (GEDIIB), and specialists on infectious diseases and vaccination (from Tropical Medicine, Infectious Diseases and Immunizations National Societies); in addition, two representatives of patient groups were included as members of the panel. When the quality of the evidence was low or there was a lack of evidence to determine the recommendations, the decisions were based on the expert opinion panel and a Delphi approach was performed. A recommendation was accepted upon achieving ≥80% agreement among the panel, including the patient representatives. As a result, eight recommendations were developed regarding the (Continued on next page)

show abstract

“…However, there is evidence that suggests that in conjunction with humoral immunity, YFV specific CD4 + T cells are preferentially activated following vaccination [20, 21•]; these activated CD4 + T cells recognize both structural and non-structural proteins and are detectable years later [22]. Conversely, YFV specific CD8 + T cells are also detectable decades after vaccination [23, 24] and correlate to initial viral loads following vaccination [25]. T cells may contribute to long-term immunity; however, it is secondary to the induction of neutralizing antibodies.…”

Section: Immune Response To Vaccination and Long-term Immunitymentioning

confidence: 99%

Live Attenuated Yellow Fever 17D Vaccine: A Legacy Vaccine Still Controlling Outbreaks In Modern Day

Collins

Barrett

2017

Curr Infect Dis Rep

View full text Add to dashboard Cite

Purpose of Review Live attenuated 17D vaccine is considered one of the safest and efficacious vaccines developed to date. This review highlights what is known and the gaps in knowledge of vaccine-induced protective immunity. Recent Findings Recently, the World Health Organization modifying its guidance from 10-year booster doses to one dose gives lifelong protection in most populations. Nonetheless, there are some data suggesting immunity, though protective, may wane over time in certain populations and more research is needed to address this question. Despite having an effective vaccine to control yellow fever, vaccine shortages were identified during outbreaks in 2016, eventuating the use of a fractional-dosing campaign in the Democratic Republic of the Congo. Summary Limited studies hinder identification of the underlying mechanism(s) of vaccine longevity; however, concurrent outbreaks during 2016 provide an opportunity to evaluate vaccine immunity following fractional dosing and insights into vaccine longevity in populations where there is limited information.

show abstract

17D yellow fever vaccine elicits comparable long-term immune responses in healthy individuals and immune-compromised patients

Cited by 41 publications

References 31 publications

Historical Perspectives on Flavivirus Research

Historical Perspectives on Flavivirus Research

Brazilian recommendations on the safety and effectiveness of the yellow fever vaccination in patients with chronic immune-mediated inflammatory diseases

Live Attenuated Yellow Fever 17D Vaccine: A Legacy Vaccine Still Controlling Outbreaks In Modern Day

Contact Info

Product

Resources

About